Loading...
  • melanoma
  • Intralesional IL-2 is commonly used to treat in-transit melanoma metastases and has a high complete response rate. (wikipedia.org)
  • In this phase II trial, the previously described IL-2 schedule (daily IL-2 for 5 days (per week) every 3 weeks) will be tested in a larger cohort of patients with melanoma to attempt to determine the response rate, median duration of response, and median survival. (clinicaltrials.gov)
  • phase
  • Moreover, during the contraction phase of an immune response where most antigen-specific CD8 + T cells disappear by apoptosis, IL-2 signals are able to rescue CD8 + T cells from cell death and provide a durable increase in memory CD8 + T-cell counts. (springer.com)
  • tyrosine
  • Activation by IL-2 led to tyrosine phosphorylation-dependent interactions between Jak3 and p52ShcA only at lower concentrations. (wikipedia.org)
  • expression
  • After costimulation from CD28 the optimal activation of expression of IL-2 and these pathways is induced. (wikipedia.org)
  • Tonsillar biopsy: Examination of tonsil tissue may provide information on the effects of IL-2 on the immune system and the expression of HIV. (clinicaltrials.gov)
  • homeostasis
  • Thus IL-2-induced mucosal homeostasis through posttranslational and transcriptional regulation of Jak3. (wikipedia.org)
  • human
  • The effects of systemic human recombinant interleukin 2 (rIL-2) infusion upon both the vasoconstrictor effect of hypocapnia and the endothelium-dependent vasodilator effect of acetylcholine (Ach) were examined in anesthetized rats equipped with cranial windows. (aacrjournals.org)
  • vitro
  • In vitro studies suggest that IL-2 may also be produced by dendritic cells and certain lymphoma cell lines. (labcorp.com)
  • Our lab and others have also found that exposure of WAS subject NK cells to IL-2 in vitro restores NK cell function and allows for normal F-actin reorganization. (knowcancer.com)
  • determine
  • Thus, the investigators propose a proof of principal clinical trial to treat WAS subjects with IL-2 to determine safety and efficacy of IL-2 in this population and if NK cell function is restored ex vivo. (knowcancer.com)
  • treatment
  • The investigators will also use the in vivo treatment of WAS subjects to forward our mechanistic studies of how IL-2 may facilitate F-actin reorganization in the absence of WASp function. (knowcancer.com)
  • Home treatment of sc IL-2: Home administration of IL-2 injections involves less frequent data and safety monitoring and no medical evaluations at the Clinical Center except at the beginning of each cycle. (clinicaltrials.gov)
  • The purpose of this study is to see if IL-2 used with potent anti-HIV drugs allows for longer HIV treatment interruptions. (clinicaltrials.gov)
  • Although treatment with IL-2 can cause temporary increases in HIV viral load, clinical studies with IL-2 have revealed no long-term adverse effects on viral load. (clinicaltrials.gov)
  • Patients will repeat this cycle of potent ART with or without IL-2, treatment interruption, and potent ART alone throughout the study. (clinicaltrials.gov)
  • response
  • Radiographic studies to evaluate for response were done after every 2 cycles (6 weeks) until disease progression or death from any cause up to 2 years. (clinicaltrials.gov)
  • Overall Response Rate (ORR) = 100%(CR + PR/total number of patients receiving Interleukin-2). (clinicaltrials.gov)
  • Duration of response is calculated as the time (months) from the date at which response is first observed (per standard Response Evaluation Criteria In Solid Tumors [RECIST] to the date of first observed disease progression or date of death from any cause, whichever came first, assessed up to 2 years. (clinicaltrials.gov)
  • Thus, IL-2 signals during different phases of an immune response are key in optimizing CD8 + T-cell functions, thereby affecting both primary and secondary responses of these T cells. (springer.com)
  • Lymphokines and the immune response: the central role of interleukin-2. (springer.com)
  • Interleukin-2 is a drug that can help stimulate the body s response to inflammation. (clinicaltrials.gov)
  • cells
  • IL-2 has essential roles in key functions of the immune system, tolerance and immunity, primarily via its direct effects on T cells. (wikipedia.org)
  • IL-2 also promotes the differentiation of T cells into effector T cells and into memory T cells when the initial T cell is also stimulated by an antigen, thus helping the body fight off infections. (wikipedia.org)
  • T he current literature on the role of interleukin (IL)-2 in memory CD8 + T-cell differentiation indicates a significant contribution of IL-2 during primary and also secondary expansion of CD8 + T cells. (springer.com)
  • Significantly, only CD8 + T cells that have received IL-2 signals during initial priming are able to mediate efficient secondary expansion following renewed antigenic challenge. (springer.com)
  • Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T-cells. (springer.com)
  • Interleukin 7 regulates the survival and generation of memory CD4 cells. (springer.com)
  • Ultrastructural studies revealed occasional morphological alterations of both vascular smooth muscle and endothelial cells in some vessels of rIL-2-infused animals but not in controls. (aacrjournals.org)
  • This study is designed as a randomized, open label trial to evaluate the effect of interleukin-2 (IL-2) on CD4 counts in patients with HIV infection and CD4 counts above 200 cells/mm(3). (clinicaltrials.gov)
  • Interleukin-2 (IL-2) helps the body make infection-fighting white blood cells, including CD4 and CD8 T cells. (clinicaltrials.gov)
  • This interaction inhibits interleukin 2 transcription in T cells. (wikipedia.org)
  • intravenously
  • IL-2 is delivered intravenously on an inpatient basis to enable proper monitoring of side effects. (wikipedia.org)
  • 3-day subcutaneous (sc) IL-2 administration: Patients currently receiving IL-2 intravenously (injections through a vein) may switch to subcutaneous administration (injections under the skin). (clinicaltrials.gov)
  • mRNA
  • Additionally, IL-2-induced downregulation of jak3-mRNA was responsible for higher IL-2-induced apoptosis in IEC. (wikipedia.org)
  • apoptosis
  • Higher concentrations of IL-2 decreased the phosphorylation of Jak3, disrupted its interactions with p52ShcA, redistributed Jak3 to the nucleus, and induced apoptosis in IEC. (wikipedia.org)
  • evaluate
  • This study will evaluate potent ART, started and interrupted based on CD4 cell counts, with or without IL-2. (clinicaltrials.gov)
  • patients
  • Patients in the randomized IL-2 study (93-CC-0113) may have tonsillar biopsies done up to three times-soon after enrollment, after month 4, and after month 12. (clinicaltrials.gov)
  • Patients with Kaposi sarcoma will also have biopsies of normal skin to allow comparison with IL-2-induced changes in the Kaposi sarcoma lesions. (clinicaltrials.gov)
  • Arm A patients will receive pulses of potent ART with IL-2, while Arm B patients will receive pulses of potent ART alone. (clinicaltrials.gov)
  • therapy
  • One approach in reconstituting an HIV-diminished immune system is the use of potent antiretroviral therapy (ART) in conjunction with IL-2. (clinicaltrials.gov)
  • cell
  • 1 In addition, IL-2 has been shown to mediate multiple immune responses on a variety of cell types. (labcorp.com)
  • At the memory stage, CD8 + T-cell frequencies can be boosted by administration of exogenous IL-2. (springer.com)
  • NK cell function, the investigators will propose a larger NIH funded efficacy trial of IL-2 in WAS. (knowcancer.com)
  • days
  • Lyophilized IL2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution IL-2 should be stored at 4°C between 2-7 days and for future use below -18°C. (prospecbio.com)
  • Prior to the functional studies, each of six animals received an i.v. infusion of rIL-2 (6 × 10 5 IU/kg) every 8 h for 3 days. (aacrjournals.org)
  • During the home cycle, the patient's case manager or other team member will place monitoring telephone calls on days 2 and 4 of the cycle and again a week later. (clinicaltrials.gov)
  • effects
  • IL-2 has a narrow therapeutic window, and the level of dosing usually determines the severity of the side effects. (wikipedia.org)